



Date: June 04, 2023

To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex Bandra (East) <u>Mumbai – 400 051</u> Stock Code : INDOCO-EQ	To The Listing Department Bombay Stock Exchange Limited Floor 25, P. J. Towers, Dalal Street, <u>Mumbai – 400 001</u> Stock Code : 532612
---	---

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Indoco Remedies Limited Clinical Research Organisation (CRO), AnaCipher, receives Clearance on Remote Record Assessment from USFDA

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Company's Clinical Research Organisation, AnaCipher, located in Hyderabad, was inspected by the United States Food and Drug Administration (USFDA) in July 2022.

The USFDA has confirmed that no objectionable conditions were observed during their remote assessment.

Commenting on this positive development, Ms. Aditi Panandikar, Managing Director, Indoco Remedies Limited, said that "This clearance by USFDA is in continuation to seventh successive FDA inspections which concluded with ZERO 483s for AnaCipher CRO. We are committed to strict adherence to all applicable guidelines and regulations and maintaining the highest quality standards in delivering quality services to our clients."

You are requested to kindly take the same on record

**Thanking you,
Yours faithfully,
For Indoco Remedies Limited**



**Ramanathan Hariharan
Company Secretary & Head- Legal**